Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional … [Read more...] about Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
Abbott
Abbott wins new FDA approvals for stent family including nod for next-gen Xience Skypoint
Abbott (NYSE:ABT) announced today that the Xience stent family received FDA approval for one-month dual antiplatelet therapy (DAPT) labeling. The FDA’s approval for one-month (as short as 28 days) DAPT labeling applies to high bleeding risk (HBR) patients in the U.S., according to a news release. The company also recently received CE mark … [Read more...] about Abbott wins new FDA approvals for stent family including nod for next-gen Xience Skypoint
How Abbott engineered a catheter-delivered device for premature babies
Abbott’s experience designing its Piccolo device provides essential lessons for medical device creators who want to spark a pediatric medical device renaissance. The Amplatzer Piccolo occluder from Abbott is one of the first medical devices that health providers can implant in premature babies weighing as little as 2 lb to treat patent ductus … [Read more...] about How Abbott engineered a catheter-delivered device for premature babies
4 catheter-based devices to watch for in 2021
Medical device companies are working to gain regulatory approvals and launch new catheter-based devices as the world slowly returns to normal after reeling from the COVID-19 pandemic. As of April 19, the FDA had approved 11 medical devices this year — two of them catheter-based. In comparison, the regulatory agency approved 19 devices by April … [Read more...] about 4 catheter-based devices to watch for in 2021
Abbott Xience stent gains expanded CE mark
Abbott (NYSE:ABT) announced today that its Xience stent received CE mark approval for a shorter duration of dual anti-platelet therapy (DAPT). The European approval for the stent allows for the DAPT to go as short as 28 days, the shortest indication available in the world for patients with high bleeding risk (HBR), according to a news … [Read more...] about Abbott Xience stent gains expanded CE mark
4 innovative devices delivered through catheters
Physicians use catheters to deploy numerous life-saving devices across the healthcare realm, from cardiovascular to neurovascular. They typically insert the thin, flexible tubes in a process called catheterization to deploy devices such as left ventricular assist devices (LVADs), transcatheter aortic valve replacements (TAVRs) and occluders to … [Read more...] about 4 innovative devices delivered through catheters
Abbott’s St. Jude Medical wins patent spat over catheterization method
St. Jude Medical, now part of Abbott, has won a patent dispute over the method for using a double catheter in heart failure patients. Niazi Licensing's patent, issued in 2003 for the double catheter system, describes it as better suited for “use in the coronary sinus, especially in patients suffering from congestive heart failure,” according to … [Read more...] about Abbott’s St. Jude Medical wins patent spat over catheterization method
Abbott touts Xience DES study results
A pair of studies of Abbott’s Xience drug-eluting stent showed no difference between shorter courses of treatment with dual antiplatelet therapy (DAPT) compared with 12 months of DAPT following implantation of the XIENCE drug-eluting stent (DES) in patients who are at a high risk of bleeding. Abbott presented the late-breaking data today at TCT … [Read more...] about Abbott touts Xience DES study results
Abbott launches study of next-gen ablation catheter
Abbott (NYSE:ABT) today announced it has enrolled the first participants in its TactiFlex PAF IDE study to evaluate the performance of the TactiFlex sensor-enabled ablation catheter. Abbott designed the catheter to treat people suffering from paroxysmal atrial fibrillation (PAF) with symptoms that are unable to be managed by … [Read more...] about Abbott launches study of next-gen ablation catheter
Abbott wins CE Mark for FlexNav delivery system
Abbott (NYSE:ABT) announced today that it won CE Mark approval in Europe for the FlexNav delivery system for its Portico transcatheter aortic valve implantation (TAVI) system. The Abbott Park, Ill.-based company’s FlexNav delivery system is designed to offer another tool for doctors to treat patients requiring a transcatheter aortic valve … [Read more...] about Abbott wins CE Mark for FlexNav delivery system
